Title: Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Journal: The New England journal of medicine 20180621
Title: Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
Journal: Clinical lymphoma, myeloma & leukemia 20160801
Title: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Journal: Nature 20091210
Title: Popovici-Muller J, et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1Mutant Cancers. ACS Med Chem Lett. 2018 Jan 19;9(4):300-305.
